Faron Pharmaceuticals investor relations material

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. It focuses on the discovery and development of anti-scarring drugs, immunotherapy treatments, and cancer vaccines. The company’s product pipeline includes Traumakine, which is used in the treatment of acute respiratory distress syndrome; Clevegen that targets the programmed cell death 1/programmed cell death ligand 1 pathway involved in tumor growth and suppression; and preclinical stage product candidates, such as Apograft for the treatment of solid tumors. Faron Pharmaceuticals Oy was founded in 2000 and is headquartered in Turku, Finland.